Cargando…

Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas

MERS-CoV is present in dromedary camels throughout the Middle East and Africa. Dromedary camels are the primary zoonotic reservoir for human infections. Interruption of the zoonotic transmission chain from camels to humans, therefore, may be an effective strategy to control the ongoing MERS-CoV outb...

Descripción completa

Detalles Bibliográficos
Autores principales: Adney, Danielle R., Wang, Lingshu, van Doremalen, Neeltje, Shi, Wei, Zhang, Yi, Kong, Wing-Pui, Miller, Megan R., Bushmaker, Trenton, Scott, Dana, de Wit, Emmie, Modjarrad, Kayvon, Petrovsky, Nikolai, Graham, Barney S., Bowen, Richard A., Munster, Vincent J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466352/
https://www.ncbi.nlm.nih.gov/pubmed/30832356
http://dx.doi.org/10.3390/v11030212
_version_ 1783411089251237888
author Adney, Danielle R.
Wang, Lingshu
van Doremalen, Neeltje
Shi, Wei
Zhang, Yi
Kong, Wing-Pui
Miller, Megan R.
Bushmaker, Trenton
Scott, Dana
de Wit, Emmie
Modjarrad, Kayvon
Petrovsky, Nikolai
Graham, Barney S.
Bowen, Richard A.
Munster, Vincent J.
author_facet Adney, Danielle R.
Wang, Lingshu
van Doremalen, Neeltje
Shi, Wei
Zhang, Yi
Kong, Wing-Pui
Miller, Megan R.
Bushmaker, Trenton
Scott, Dana
de Wit, Emmie
Modjarrad, Kayvon
Petrovsky, Nikolai
Graham, Barney S.
Bowen, Richard A.
Munster, Vincent J.
author_sort Adney, Danielle R.
collection PubMed
description MERS-CoV is present in dromedary camels throughout the Middle East and Africa. Dromedary camels are the primary zoonotic reservoir for human infections. Interruption of the zoonotic transmission chain from camels to humans, therefore, may be an effective strategy to control the ongoing MERS-CoV outbreak. Here we show that vaccination with an adjuvanted MERS-CoV Spike protein subunit vaccine confers complete protection from MERS-CoV disease in alpaca and results in reduced and delayed viral shedding in the upper airways of dromedary camels. Protection in alpaca correlates with high serum neutralizing antibody titers. Lower titers of serum neutralizing antibodies correlate with delayed and significantly reduced shedding in the nasal turbinates of dromedary camels. Together, these data indicate that induction of robust neutralizing humoral immune responses by vaccination of naïve animals reduces shedding that potentially could diminish the risk of zoonotic transmission.
format Online
Article
Text
id pubmed-6466352
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64663522019-04-18 Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas Adney, Danielle R. Wang, Lingshu van Doremalen, Neeltje Shi, Wei Zhang, Yi Kong, Wing-Pui Miller, Megan R. Bushmaker, Trenton Scott, Dana de Wit, Emmie Modjarrad, Kayvon Petrovsky, Nikolai Graham, Barney S. Bowen, Richard A. Munster, Vincent J. Viruses Article MERS-CoV is present in dromedary camels throughout the Middle East and Africa. Dromedary camels are the primary zoonotic reservoir for human infections. Interruption of the zoonotic transmission chain from camels to humans, therefore, may be an effective strategy to control the ongoing MERS-CoV outbreak. Here we show that vaccination with an adjuvanted MERS-CoV Spike protein subunit vaccine confers complete protection from MERS-CoV disease in alpaca and results in reduced and delayed viral shedding in the upper airways of dromedary camels. Protection in alpaca correlates with high serum neutralizing antibody titers. Lower titers of serum neutralizing antibodies correlate with delayed and significantly reduced shedding in the nasal turbinates of dromedary camels. Together, these data indicate that induction of robust neutralizing humoral immune responses by vaccination of naïve animals reduces shedding that potentially could diminish the risk of zoonotic transmission. MDPI 2019-03-02 /pmc/articles/PMC6466352/ /pubmed/30832356 http://dx.doi.org/10.3390/v11030212 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Adney, Danielle R.
Wang, Lingshu
van Doremalen, Neeltje
Shi, Wei
Zhang, Yi
Kong, Wing-Pui
Miller, Megan R.
Bushmaker, Trenton
Scott, Dana
de Wit, Emmie
Modjarrad, Kayvon
Petrovsky, Nikolai
Graham, Barney S.
Bowen, Richard A.
Munster, Vincent J.
Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
title Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
title_full Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
title_fullStr Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
title_full_unstemmed Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
title_short Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas
title_sort efficacy of an adjuvanted middle east respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466352/
https://www.ncbi.nlm.nih.gov/pubmed/30832356
http://dx.doi.org/10.3390/v11030212
work_keys_str_mv AT adneydanieller efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT wanglingshu efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT vandoremalenneeltje efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT shiwei efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT zhangyi efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT kongwingpui efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT millermeganr efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT bushmakertrenton efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT scottdana efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT dewitemmie efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT modjarradkayvon efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT petrovskynikolai efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT grahambarneys efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT bowenricharda efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas
AT munstervincentj efficacyofanadjuvantedmiddleeastrespiratorysyndromecoronavirusspikeproteinvaccineindromedarycamelsandalpacas